The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The private equity firms expect to close the deal in the first half of 2026 with a valuation of up to $79 per share.

The firm's diagnostics revenues rose 4 percent to $2.46 billion, partially due to the growth of respiratory disease testing-related revenues from Cepheid.

Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.